New lupus drug alnuctamab enters early human testing

NCT ID NCT07219563

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug, alnuctamab, in 21 people with moderate to severe lupus that hasn't improved with standard treatments. The drug is given as an injection under the skin, and participants will stay in the hospital for 9 days after the first dose. The main goals are to check safety and find the right dose, while also looking at whether it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alnuctamab (a drug given as an injection under the skin)
What this could lead to: If it works, this could point toward a new treatment option for people with lupus that hasn't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 21 people, so it's mainly checking safety. It may not work, and side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.